Northwest Biotherapeutics
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$22.66M
-0.3
-0.08
$1.38M
25
The company is headquartered in Bethesda, Maryland and currently employs 25 full-time employees. The company went IPO on 2001-12-14.
Northwest Biotherapeutics appointed Dr. Annalisa Jenkins as a Strategic Adviser to enhance their DCVax® platform's advancement in treating solid tumors, particularly glioblastoma.
The company is headquartered in Bethesda, Maryland and currently employs 25 full-time employees. The company went IPO on 2001-12-14.
Recently from Cashu
Northwest Biotherapeutics Expands Manufacturing Capacity with New Grade C Suite for DCVax® Therapies
Northwest Biotherapeutics Expands Manufacturing Capacity with New Grade C Suite Northwest Biotherapeutics, a biotechnology firm dedicated to developing DCVax® personalized immune therapies for solid t…
Northwest Biotherapeutics Expands Manufacturing with New Grade C Suite for Cancer Therapies
Northwest Biotherapeutics Advances Manufacturing Capabilities with New Grade C Suite Northwest Biotherapeutics (OTCQB:NWBO), a biotechnology firm dedicated to developing personalized immune therapies…
Northwest Biotherapeutics Acquires Advent BioServices to Enhance Manufacturing and Cancer Treatment
Northwest Biotherapeutics Expands Capabilities with Advent BioServices Acquisition Northwest Biotherapeutics, Inc. has successfully finalized its acquisition of Advent BioServices Ltd., a strategic mo…
Northwest Biotherapeutics (NWBO) Acquires Advent BioServices to Enhance Operational Efficiency and Growth
Northwest Biotherapeutics Expands Capabilities with Advent BioServices Acquisition Northwest Biotherapeutics, Inc. (NWBO), a biotechnology company dedicated to developing personalized immune therapies…